INVA Innoviva, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: diversified biopharmaceutical company with royalties portfolio plus critical care and infectious disease operating platform (Innoviva Specialty Therapeutics)
• • New products launched: XACDURO® (2023), ZEVTERA® (Q3 2025), and FDA approval of NUZOLVENCE® (Dec 2025) for infectious diseases
• • Strategic shift: transformation from pure-play royalty business to diversified biopharma with fast-growing, differentiated operating platform
• • Notable metric: XACDURO® Phase 3 ATTACK trial showed 19.0% mortality vs 32.3% for colistin; approved in US (2023) and China (2024)
• • Unusual fact: XACDURO® named preferred treatment for carbapenem-resistant Acinetobacter baumannii in 2024 IDSA guidelines

Risk Factors

• • FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing
• • Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio
• • Supply vulnerability from Zai Lab interim supply agreement for XACDURO® ex-U.S. sales, accounting for significant 218% YoY increase to $40.9M
• • Competition risk from established respiratory products RELVAR®/BREO® and ANORO® ELLIPTA® partnered with GSK, with royalties tiered 15% up to $3B sales then 5%
• • $300M capital locked in ISP Fund with Sarissa Capital as advisor and withdrawal restrictions, creating financial liquidity and concentration risk until April 2026 distributions

Management Discussion & Analysis

• • Revenue details and YoY change not disclosed in provided MD&A excerpt
• • Profitability or margin data not included in provided text
• • Segment performance metrics not available in excerpt
• • Cash flow, buybacks, dividends, capex information not provided
• • Forward-looking statements referenced with risks, no specific guidance or outlook given

What are the latest INVA SEC filings in 2026?

Innoviva, Inc. (INVA) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did INVA file its most recent 10-K annual report?

Innoviva, Inc. (INVA) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view INVA 10-Q quarterly reports?

Innoviva, Inc. (INVA)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every INVA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has INVA filed recently?

Innoviva, Inc. (INVA)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find INVA insider trading activity (Form 4)?

SignalX aggregates every INVA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does INVA file with the SEC?

Innoviva, Inc. (INVA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INVA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Innoviva, Inc. (INVA).

What is INVA's SEC CIK number?

Innoviva, Inc. (INVA)'s SEC CIK (Central Index Key) number is 1080014. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1080014 to look up all INVA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find INVA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Innoviva, Inc. (INVA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.